Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic amyloidosis.

Helen J Lachmann1, Philip N Hawkins

  • 1National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, Royal Free Campus, London NW3 2PF, UK. h.lachmann@medsch.ucl.ac.uk

Current Opinion in Pharmacology
|February 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biochemical triple testing to exclude monoclonal gammopathy for non-biopsy diagnosis of transthyretin amyloid cardiomyopathy.

European journal of heart failure·2026
Same author

Monoclonal gammopathy exclusion in transthyretin amyloid cardiomyopathy: iStopMM estimated glomerular filtration rate-adjusted serum-free light chain ratio cut-offs.

European heart journal·2026
Same author

Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps.

Blood·2026
Same author

Reply to "Correspondence on: EULAR/PRES endorsed recommendations for the management of FMF: 2024 update".

Annals of the rheumatic diseases·2026
Same author

Efficacy of Suppression of Serum Transthyretin With Patisiran and Vutrisiran in Variant ATTR Amyloidosis: An Observational Crossover Study.

Circulation·2026
Same author

Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.

JACC. Heart failure·2026
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Amyloidosis involves abnormal protein deposits in organs, posing diagnostic challenges. Novel therapies target amyloid formation and deposits, potentially treating rare systemic forms and common diseases like Alzheimer's and type II diabetes.

Area of Science:

  • Biochemistry
  • Pathology
  • Medicine

Background:

  • Amyloidosis is a group of diseases characterized by abnormal extracellular deposition of insoluble protein fibrils.
  • These conditions affect multiple organ systems and present significant diagnostic and management difficulties.

Purpose of the Study:

  • To summarize the current understanding of amyloidosis.
  • To discuss emerging therapeutic strategies targeting amyloid formation and deposits.

Main Methods:

  • Review of current literature on amyloidosis pathogenesis and treatment.
  • Analysis of novel therapeutic approaches including fibrillogenesis inhibition and amyloid destabilization.

Main Results:

  • Current treatments focus on reducing precursor protein supply and supportive care.

Related Experiment Videos

  • Emerging strategies aim to inhibit amyloid formation or break down existing deposits.

    • Conclusions:

    • Advances in understanding amyloid formation are driving novel therapeutic development.
    • These novel strategies may offer effective treatments for systemic amyloidosis, Alzheimer's disease, and type II diabetes.